Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00102921 | Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease | PHASE2 | COMPLETED | 70 | — | — | Aug 1, 2004 | Dec 1, 2005 | Mar 6, 2025 | 14 | United States |
| Name | Type | Description |
|---|---|---|
| CCX282-B | DRUG | - |
Inclusion Criteria: * Diagnosis of moderate to severe Crohn's Disease in small intestine; disease must be active at the time of study entry * Use of adequate and approved methods of birth control throughout the study period * Willing and able to sign an informed consent Exclusion Criteria: * Preg...